PLANEGG/MUNICH, GERMANY / ACCESSWIRE / January 8, 2024 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) today announced that Jean-Paul Kress, M.D., Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 3:00 p.m. PST in San Francisco, California. The company's Chief Financial Officer, Lucinda Crabtree, Ph.D., and Chief Research and Development Officer, Tim Demuth, M.D., Ph.D., will also be in attendance and available to address questions.
A live webcast of the presentation can be accessed on the Investors section of MorphoSys' website at https://www.morphosys.com/en/investors. An archived version of the webcast will be available on the company's website following the presentation.
About MorphoSys
At MorphoSys, we are driven by our mission: More life for people with cancer . As a global commercial-stage biopharmaceutical company, we develop and deliver innovative medicines, aspiring to redefine how cancer is treated. MorphoSys is headquartered in Planegg, Germany, and has its U.S. operations anchored in Boston, Massachusetts. To learn more, visit us at www.morphosys.com and follow us on Twitter at X and LinkedIn.
For more information, please contact:
| Media Contacts: Thomas Biegi Senior Vice President, Corporate Affairs Tel: +49 (0)151 / 74612318 This email address is being protected from spambots. You need JavaScript enabled to view it. | Investor Contact: Dr. Julia Neugebauer Vice President, Global Investor Relations Tel: +49 (0)89 / 899 27 179 This email address is being protected from spambots. You need JavaScript enabled to view it. |
Eamonn Nolan Director, Corporate Communications & Investor Relations Tel: +1 617-548-9271 This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$18.96 |
| Daily Volume: | 0 |
| Market Cap: | US$2.860B |
June 20, 2024 April 29, 2024 April 24, 2024 March 13, 2024 December 10, 2023 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
